Not on ACE-i
Not on BB
Adverse effects
32/52 (61.5%)
15/50 (30%)
Use of alt 1
st
line Mx to ACE-I
12/52 (23%)
9/50 (18%)
Use of 2
nd
line Mx
15/52 (28.8%)
15/50 (30%)
Use of single1st line Mx
7/52 (13.4%)
6/50 (12%)
Table 2:
Comparing side effects and the use of alternative agents between patients who did not receive ACE-I and the ones who did not receive BB.
